“After extensive analysis of the clinical and safety data sets and the drug product administered to participants during the double-blind phase of the study, we continue to believe neflamapimod may ...

The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus ...

DLB's fiscal first-quarter 2025 performance gains from steady growth in the Licensing, and the Products and services segments.

Barrington analyst Patrick Sholl maintained a Buy rating on Dolby Laboratories (DLB – Research Report) today and set a price target of $100.00.

In a report released yesterday, Steve Frankel from Rosenblatt Securities reiterated a Buy rating on Dolby Laboratories (DLB – Research Report), ...

Dolby Laboratories (NYSE:DLB) reported its financial results for the first quarter of 2025, surpassing earnings expectations ...

Dolby Laboratories (DLB) delivered earnings and revenue surprises of 6.54% and 3.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Here's a brief overview of the earnings report. Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up $41.42 million from the same ...

Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up ...

Dolby Laboratories Inc DLB is slated to report first-quarter fiscal 2025 results on Jan. 29. Stay up-to-date with all ...

Barrington Research restated their outperform rating on shares of Dolby Laboratories (NYSE:DLB – Free Report) in a research note published on Monday,Benzinga reports. The firm currently has a $100.00 ...